Table 4

Comparison of intraoperative and postoperative outcomes between the 2 groups, by tumour type

Characteristic; indicationGroup; mean ± SD*p value
PRATLA
No. of doses of narcotic, median (IQR)
 All tumour types2.5 (1.0–4.8)3.0 (1.0–7.0)0.07§
 Excluding pheochromocytoma2.5 (1.0–4.0)4.0 (2.0–6.5)0.07§
 Pheochromocytoma3.5 (1.0–7.5)2.5 (1.0–7.5)0.8§
 Primary aldosteronism2.5 (1.0–4.2)4.0 (2.0–5.0)0.4§
 Cushing syndrome1.5 (0.0–4.0)35.0 (17.5–38)0.2§
 Nonfunctional2.0 (0.0–4.5)2.0 (2.0–6.5)0.3§
Anesthesia time, min
 All tumour types51.5 ± 11.563.7 ± 17.3< 0.001
 Excluding pheochromocytoma50.4 ± 10.654.8 ± 10.30.07
 Pheochromocytoma61.3 ± 15.275.0 ± 17.90.01
 Primary aldosteronism49.8 ± 8.357.1 ± 11.30.1
 Cushing syndrome58.5 ± 16.452.0 ± 5.60.4
 Nonfunctional45.2 ± 9.353.6 ± 10.90.09
Operative time, min
 All tumour types77.9 ± 40.4118.4 ± 47.4< 0.001
 Excluding pheochromocytoma79.5 ± 41.6105.4 ± 22.3< 0.001
 Pheochromocytoma64.2 ± 26.9135.1 ± 64.10.005
 Primary aldosteronism77.7 ± 44.9103.7 ± 21.10.001
 Cushing syndrome67.0 ± 18.093.7 ± 12.50.04
 Nonfunctional99.9 ± 39.0110.0 ± 25.30.5
Length of stay, median (IQR), d
 All tumour types2.0 (2.0–3.0)4.0 (3.0–5.0)< 0.001§
 Excluding pheochromocytoma2.0 (2.0–3.0)3.0 (2.0–3.5)0.01§
 Pheochromocytoma2.0 (2.0–2.8)5.0 (4.0–5.8)< 0.001
 Primary aldosteronism2.0 (2.0–3.0)3.0 (2.0–3.0)0.08§
 Cushing syndrome4.0 (3.0–5.0)7.0 (5.0–7.0)0.3
 Nonfunctional2.0 (1.0–2.0)2.0 (2.0–3.0)0.009§
  • IQR = interquartile range; PRA = posterior retroperitoneoscopic adrenalectomy; SD = standard deviation; TLA = transperitoneal laparoscopic adrenalectomy.

  • * Except where noted otherwise.

  • Time from patient entry into the operating room to initial incision.

  • Time from initial incision to completion of skin closure.

  • § Wilcoxon rank-sum test.

  • t test.